An association between resting state EEG parameters and the severity of topiramate-related cognitive impairment

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: Many commonly prescribed drugs cause cognitive deficits. We investigated whether parameters of the resting-state electroencephalogram (rsEEG) are related to the severity of cognitive impairments associated with administration of the antiseizure drug topiramate (TPM) and the benzodiazepine lorazepam (LZP). Methods: We conducted a double-blind, randomized, placebo-controlled crossover study. After a baseline visit, subjects completed three sessions at which they received either a single dose of TPM, LZP, or placebo. Four-hours after drug administration and at baseline, subjects completed a working memory (WM) task after their rsEEG was recorded. After quantifying drug-related behavioral (WM accuracy (ACC)/reaction time (RT)) and electrophysiological (alpha, theta, beta (1,2), gamma power) change for each subject, we constructed drug-specific mixed effects models of change for each WM and EEG measure. Regression models were constructed to characterize the relationship between baseline rsEEG measures and drug-related performance changes. Results: Linear mixed effects models showed theta power increases in response to TPM administration. The results of the regression models revealed a number of robust relationships between baseline rsEEG parameters and TPM-related, but not LZP-related, WM impairment. Conclusions: We showed for the first time that parameters of the rsEEG are associated with the severity of TPM-related WM deficits; this suggests that rsEEG measures may have novel clinical applications in the future.

Original languageEnglish (US)
Article number107598
JournalEpilepsy and Behavior
StatePublished - Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Inc.


  • Drug-related cognitive impairment
  • Resting-state EEG


Dive into the research topics of 'An association between resting state EEG parameters and the severity of topiramate-related cognitive impairment'. Together they form a unique fingerprint.

Cite this